CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 198 filers reported holding CHEMOCENTRYX INC in Q2 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $118,000 | -44.3% | 2,292 | -40.7% | 0.01% | -57.1% |
| Q3 2020 | $212,000 | -7.0% | 3,867 | -2.9% | 0.01% | -6.7% |
| Q2 2020 | $228,000 | +128.0% | 3,981 | +61.0% | 0.02% | +87.5% |
| Q1 2020 | $100,000 | +455.6% | 2,473 | +430.7% | 0.01% | +700.0% |
| Q4 2019 | $18,000 | -57.1% | 466 | -89.7% | 0.00% | -66.7% |
| Q2 2019 | $42,000 | -51.2% | 4,543 | -26.4% | 0.00% | -57.1% |
| Q1 2019 | $86,000 | +168.8% | 6,176 | +103.5% | 0.01% | +133.3% |
| Q4 2018 | $32,000 | -20.0% | 3,035 | -2.7% | 0.00% | 0.0% |
| Q3 2018 | $40,000 | -100.0% | 3,118 | -53.1% | 0.00% | -62.5% |
| Q2 2018 | $87,621,000 | +973466.7% | 6,653 | +944.4% | 0.01% | +700.0% |
| Q1 2018 | $9,000 | +125.0% | 637 | -11.0% | 0.00% | – |
| Q4 2017 | $4,000 | +300.0% | 716 | +383.8% | 0.00% | – |
| Q3 2017 | $1,000 | 0.0% | 148 | 0.0% | 0.00% | – |
| Q2 2017 | $1,000 | -83.3% | 148 | -83.8% | 0.00% | -100.0% |
| Q1 2017 | $6,000 | -14.3% | 916 | +2.8% | 0.00% | 0.0% |
| Q4 2016 | $7,000 | – | 891 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |